Pharmacological Treatment of Acute Unilateral Vestibulopathy: A Review

키워드

참고문헌 (113)

1. Strupp M, "Vestibular disorders", Dtsch Arztebl Int, 117, pp.300~310 (2020)
2. Sekitani T, "Vestibular neuronitis : epidemiological survey by questionnaire in Japan", Acta Otolaryngol Suppl, 503, pp.9~12 (1993)
3. Strupp M, "Acute unilateral vestibulopathy", Neurol Clin, 33, pp.669~685 (2015)
4. Casani AP, "Current insights into treating vertigo in older adults", Drugs Aging, 38, pp.655~670 (2021)
5. Curthoys IS, "Vestibular compensation and substitution", Curr Opin Neurol, 13, pp.27~30 (2000)
6. Lacour M, "Vestibular compensation : the neuro-otologist’s best friend", J Neurol, 263(Suppl 1), pp.S54~S64 (2016)
7. Swamy Suman N, "Measure of central vestibular compensation : a review", J Int Adv Otol, 18, pp.441~446 (2022)
8. Komazec Z, "Specific vestibular exercises in the treatment of vestibular neuritis", Med Pregl, 57, pp.269~274 (2004)
9. Low KJY, "Anticholinergic drugs interact with neuroprotective chaperone L-PGDS and modulate cytotoxicity of Aβ amyloids", Front Pharmacol, 11, pp.862~ (2020)
10. Soto E, "Neuropharmacology of vestibular system disorders", Curr Neuropharmacol, 8, pp.26~40 (2010)
11. Svoboda J, "Drugs interfering with muscarinic acetylcholine receptors and their effects on place navigation", Front Psychiatry, 8, pp.215~ (2017)
12. Renner UD, "Pharmacokinetics and pharmacodynamics in clinical use of scopolamine", Ther Drug Monit, 27, pp.655~665 (2005)
13. Bajo R, "Scopolamine effects on functional brain connectivity : a pharmacological model of Alzheimer’s disease", Sci Rep, 5, pp.9748~ (2015)
14. Winter J, "Transdermal scopolamine in nausea and vomiting", Drug Intell Clin Pharm, 21, pp.712~714 (1987)
15. Antor MA, "The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting", Front Pharmacol, 5, pp.55~ (2014)
16. Nachum Z, "Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications", Clin Pharmacokinet, 45, pp.543~566 (2006)
17. Gordon CR, "Recurrent classic migraine attacks following transdermal scopolamine intoxication", Headache, 31, pp.172~174 (1991)
18. Barceló B, "Diminished consciousness in a woman following an unsuspected scopolamine overdose", J Anal Toxicol, 45, pp.e7~e14 (2021)
19. Castaño Pérez GA, "Use of emerging drugs in Medellín, Colombia", Rev Colomb Psiquiatr, 42, pp.248~256 (2013)
20. Müller J, "Toxic psychoses from atropine and scopolamine", Fortschr Neurol Psychiatr, 66, pp.289~295 (1998)
21. Zabirowicz ES, "Pharmacology and Physiology for Anesthesia", pp.671~692 (2019), Elsevier
22. Babin RW, "Transdermal scopolamine in the treatment of acute vertigo", Ann Otol Rhinol Laryngol, 93(1 Pt 1), pp.25~27 (1984)
23. Schmitt LG, "Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine", Arch Otolaryngol Head Neck Surg, 112, pp.88~91 (1986)
24. Lau SH, "Scopolamine patch withdrawal syndrome", Hosp Pharm, 49, pp.218~220 (2014)
25. Scholtz AW, "Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate : a doubleblind, randomized, parallel-group clinical study", Clin Ther, 26, pp.866~877 (2004)
26. Cohen B, "Meclizine and placebo in treating vertigo of vestibular origin. Relative efficacy in a double-blind study", Arch Neurol, 27, pp.129~135 (1972)
27. Huppert D, "Which medication do I need to manage dizzy patients?", Acta Otolaryngol, 131, pp.228~241 (2011)
28. Sherman CR, "Motion sickness : review of causes and preventive strategies", J Travel Med, 9, pp.251~256 (2002)
29. Jørgensen EA, "Histamine and the regulation of body weight", Neuroendocrinology, 86, pp.210~214 (2007)
30. Shih RD, "Diazepam and meclizine are equally effective in the treatment of vertigo : an emergency department randomized double-blind placebocontrolled trial", J Emerg Med, 52, pp.23~27 (2017)
31. Marken PA, "Anticholinergic drug abuse and misuse", CNS Drugs, 5, pp.190~199 (1996)
32. Patel PN, "Meclizine : safety and efficacy in the treatment and prevention of motion sickness", Clin Med Insights Ther, 3, pp.CMT.S6237~ (2011)
33. Dyhrfjeld-Johnsen J, "Management of peripheral vertigo with antihistamines : new options on the horizon", Br J Clin Pharmacol, 85, pp.2255~2263 (2019)
34. Takumida M, "Localization of histamine(H1, H2, H3 and H4)receptors in mouse inner ear", Acta Otolaryngol, 136, pp.537~544 (2016)
35. Amini A, "Histamine antagonists for treatment of peripheral vertigo : a meta-analysis", J Int Adv Otol, 11, pp.138~142 (2015)
36. Adrion C, "Efficacy and safety of betahistine treatment in patients with Meniere’s disease : primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial(BEMED trial)", BMJ, 352, pp.h6816~ (2016)
37. Redon C, "Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss", J Clin Pharmacol, 51, pp.538~548 (2011)
38. Parfenov VA, "Effectiveness of betahistine(48 mg", day)in patients with vestibular vertigo during routine practice : the VIRTUOSO study, 2017, pp.12, e0174114~
39. Petremann M, "Effect of the novel histamine H4 receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss", Br J Pharmacol, 177, pp.623~633 (2020)
40. Venail F, "Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H4 receptor inhibitor SENS-111using a modified caloric test in healthy subjects", Br J Clin Pharmacol, 84, pp.2836~2848 (2018)
41. Christofaki M, "Ondansetron : a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting", Expert Opin Drug Metab Toxicol, 10, pp.437~444 (2014)
42. Saberi A, "Ondansetron or promethazine : which one is better for the treatment of acute peripheral vertigo?", Am J Otolaryngol, 40, pp.10~15 (2019)
43. Braude D, "Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department : a randomized, double-blind, noninferiority trial", Acad Emerg Med, 15, pp.209~215 (2008)
44. Dyhrfjeld-Johnsen J, "Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury", J Vestib Res, 23, pp.177~186 (2013)
45. Venail F, "A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study", Eur Ann Otorhinolaryngol Head Neck Dis, 129, pp.65~68 (2012)
46. Sadawarte P, "Comparative study of oral vs IV ondansetron for reducing PONV in patients undergoing laparoscopic surgery under general anesthesia", Int J Pharm Sci Invent, 4, pp.1~6 (2015)
47. Roila F, "Ondansetron clinical pharmacokinetics", Clin Pharmacokinet, 29, pp.95~109 (1995)
48. Butcher ME, "Global experience with ondansetron and future potential", Oncology, 50, pp.191~197 (1993)
49. Montgomery AM, "The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission", J Neural Transm Gen Sect, 91, pp.1~11 (1993)
50. Tyers MB, "Pharmacology and preclinical antiemetic properties of ondansetron", Semin Oncol, 19(4 Suppl 10), pp.1~8 (1992)
51. Zajonc TP, "Vertigo and motion sickness. Part II : pharmacologic treatment", Ear Nose Throat J, 85, pp.25~35 (2006)
52. Jagdale SC, "Hydroxyl ethyl cellulose HHX and polymethyl methacrylate based site specific floating delivery of prochlorperazine maleate", Open Pharm Sci J, 3, pp.149~163 (2016)
53. Singh AK, "Prochlorperazine versus cinnarizine in cases of vertigo", Indian J Otolaryngol Head Neck Surg, 50, pp.392~397 (1998)
54. Johnson WH, "The control of vertigo by thiethylperazine", Arch Otolaryngol, 82, pp.261~266 (1965)
55. Moser JD, "No more than necessary : safety and efficacy of low-dose promethazine", Ann Pharmacother, 40, pp.45~48 (2006)
56. Dougherty MM, "Encyclopedia of Toxicology", pp.881~883 (2014), Academic Press
57. Smith HS, "Dopamine receptor antagonists", Ann Palliat Med, 1, pp.137~142 (2012)
58. Ercin D, "Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study", Am J Emerg Med, 40, pp.77~82 (2021)
59. Johnson WH, "Effects of droperidol in management of vestibular disorders", Laryngoscope, 86, pp.946~954 (1976)
60. Oosterveld WJ, "The combined effect of cinnarizine and domperidone on vestibular susceptibility", Aviat Space Environ Med, 58, pp.218~223 (1987)
61. Irving C, "Droperidol for the treatment of acute peripheral vertigo", Am J Emerg Med, 17, pp.109~110 (1999)
62. Holstein GR, "The ultrastructure of GABAimmunoreactive vestibular commissural neurons related to velocity storage in the monkey", Neuroscience, 93, pp.171~181 (1999)
63. Holstein GR, "Ultrastructural observations of efferent terminals in the crista ampullaris of the toadfish, opsanus tau", Exp Brain Res, 155, pp.265~273 (2004)
64. Sekitani T, "Drug effects on the medial vestibular nucleus", Arch Otolaryngol, 93, pp.581~589 (1971)
65. Ganança MM, "Clonazepam in the pharmacological treatment of vertigo and tinnitus", Int Tinnitus J, 8, pp.50~53 (2002)
66. Stensrud P, "Clonazepam(rivotril)in migraine prophylaxis", Headache, 19, pp.333~334 (1979)
67. Ferrary E, "Calcium and the inner ear fluids", Acta Otolaryngol Suppl, 460, pp.13~17 (1988)
68. Mammano F, "Ca2+ signaling in the inner ear", Physiology(Bethesda), 22, pp.131~144 (2007)
69. Soto E, "Neuropharmacological basis of vestibular system disorder treatment", J Vestib Res, 23, pp.119~137 (2013)
70. Lee JA, "Calcium antagonists in the prevention of motion sickness", Aviat Space Environ Med, 57, pp.45~48 (1986)
71. Lepcha A, "Flunarizine in the prophylaxis of migrainous vertigo : a randomized controlled trial", Eur Arch Otorhinolaryngol, 271, pp.2931~2936 (2014)
72. Oosterveld WJ, "Vestibular pharmacology of flunarizine compared to that of cinnarizine", ORL J Otorhinolaryngol Relat Spec, 36, pp.157~164 (1974)
73. Fields T, "A master protocol to investigate a novel therapy acetyl-Lleucine for three ultra-rare neurodegenerative diseases : Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia", Trials, 22, pp.84~ (2021)
74. Churchill GC, "Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance", PLoS One, 15, pp.e0229585~ (2020)
75. Günther L, "N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus", PLoS One, 10, pp.e0120891~ (2015)
76. Beck R, "The mixed blessing of treating symptoms in acute vestibular failure--evidence from a 4-aminopyridine experiment", Exp Neurol, 261, pp.638~645 (2014)
77. Strupp M, "Aminopyridines for the treatment of neurologic disorders", Neurol Clin Pract, 7, pp.65~76 (2017)
78. Alviña K, "The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia", J Neurosci, 30, pp.7258~7268 (2010)
79. Etzion Y, "Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells", Exp Brain Res, 139, pp.419~425 (2001)
80. Jen JC, "Primary episodic ataxias : diagnosis, pathogenesis and treatment", Brain, 130(Pt 10), pp.2484~2493 (2007)
81. Kalla R, "Aminopyridines and acetyl-DL-leucine : new therapies in cerebellar disorders", Curr Neuropharmacol, 17, pp.7~13 (2019)
82. Mitoma H, "The physiological basis of therapies for cerebellar ataxias", Ther Adv Neurol Disord, 9, pp.396~413 (2016)
83. Hiyoshi M, "Vertigo consistent with the so-called vestibular neuronitis after influenza vaccination", Pract Oto-Rhino-Laryngol, 75(supplement 1), pp.260~265 (1982)
84. Davis LE, "Viruses and vestibular neuritis : review of human and animal studies", Acta Otolaryngol Suppl, 113(sup503), pp.70~73 (1993)
85. Bumm P, "Lymphocyte subpopulations and HLA-DR determinations in diseases of the inner ear and Bell’s palsy", HNO, 34, pp.525~527 (1986)
86. Oh EH, "Neutrophil-mediated immune response as a possible mechanism of acute unilateral vestibulopathy", J Vestib Res, 30, pp.363~374 (2020)
87. Kassner SS, "Proinflammatory activation of peripheral blood mononuclear cells in patients with vestibular neuritis", Audiol Neurootol, 16, pp.242~247 (2011)
88. Strupp M, "Methylprednisolone, valacyclovir, or the combination for vestibular neuritis", N Engl J Med, 351, pp.354~361 (2004)
89. Hegemann SCA, "Diagnosis and treatment of vestibular neuritis", neuronitis or peripheral vestibulopathy (PVP)? Open questions and possible answers, 2017, pp.38, 626~631
90. Leong KJ, "Systematic review and meta-analysis : effectiveness of corticosteroids in treating adults with acute vestibular neuritis", Otolaryngol Head Neck Surg, 165, pp.255~266 (2021)
91. El Mahmoudi N, "Breaking a dogma : acute anti-inflammatory treatment alters both post-lesional functional recovery and endogenous adaptive plasticity mechanisms in a rodent model of acute peripheral vestibulopathy", J Neuroinflammation, 18, pp.183~ (2021)
92. Milionis HJ, "Lipoprotein(a)and acute-phase response in patients with vestibular neuronitis", Eur J Clin Invest, 33, pp.1045~1050 (2003)
93. Fattori B, "Relevance of plasma D-dimer measurement in patients with acute peripheral vertigo", J Laryngol Otol, 117, pp.467~472 (2003)
94. Bartual-Pastor J, "Vestibular neuritis : etiopathogenesis", Rev Laryngol Otol Rhinol(Bord), 126, pp.279~281 (2005)
95. Oron Y, "Cardiovascular risk factors among patients with vestibular neuritis", Ann Otol Rhinol Laryngol, 126, pp.597~601 (2017)
96. Liqun Z, "Acute unilateral audiovestibulopathy due to embolic labyrinthine infarction", Front Neurol, 9, pp.311~ (2018)
97. Sokolova L, "Treatment of vertigo : a randomized, double-blind trial comparing efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine", Int J Otolaryngol, 2014, pp.682439~ (2014)
98. Mehlsen J, "Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers", Clin Physiol Funct Imaging, 22, pp.375~378 (2002)
99. Lindner M, "Ginkgo biloba extract EGb 761 improves vestibular compensation and modulates cerebral vestibular networks in the rat", Front Neurol, 10, pp.147~ (2019)
100. Duverger D, "Effects of repeated treatments with an extract of Ginkgo biloba(EGb 761)on cerebral glucose utilization in the rat : an autoradiographic study", Gen Pharmacol, 26, pp.1375~1383 (1995)
101. Lacour M, "Plasticity mechanisms in vestibular compensation in the cat are improved by an extract of Ginkgo biloba(EGb 761)", Pharmacol Biochem Behav, 40, pp.367~379 (1991)
102. Dix MR, "The pathology symptomatology and diagnosis of certain common disorders of the vestibular system", Proc R Soc Med, 45, pp.341~354 (1952)
103. Schuknecht HF, "Second Louis H. Clerf lecture. Vestibular neuritis", Ann Otol Rhinol Laryngol Suppl, 90(1 Pt 2), pp.1~19 (1981)
104. Arbusow V, "Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia : implications for vestibular neuritis", Ann Neurol, 46, pp.416~419 (1999)
105. Castellucci A, "Case report : filling defect in posterior semicircular canal on MRI with balanced steady-state gradient-echo sequences after labyrinthine ischemia in the common cochlear artery territory as an early sign of fibrosis", Front Neurol, 11, pp.608838~ (2021)
106. Ardıç FN, "Evidence-based medical treatment in peripheral vestibular diseases", Turk Arch Otolaryngol, 52, pp.61~66 (2014)
107. Heffernan A, "Virtual and augmented reality in the vestibular rehabilitation of peripheral vestibular disorders : systematic review and meta-analysis", Sci Rep, 11, pp.17843~ (2021)
108. Lu YC, "Vertigo from herpes zoster oticus : superior or inferior vestibular nerve origin?", Laryngoscope, 113, pp.307~311 (2003)
109. Fetter M, "Vestibular neuritis spares the inferior division of the vestibular nerve", Brain, 119(Pt 3), pp.755~763 (1996)
110. Gianoli G, "Anatomic differences in the lateral vestibular nerve channels and their implications in vestibular neuritis", Otol Neurotol, 26, pp.489~494 (2005)
111. Fawzy M, "Bilateral vestibulopathy treatment : update and future directions", Egypt J Otolaryngol, 32, pp.83~92 (2016)
112. Hashimoto M, "Diagnostic and therapeutic strategies for vestibular neuritis of the Japan society for equilibrium research", Auris Nasus Larynx (2022)[DOI]
113. Bogdanova A, "Corticosteroids in patients with vestibular neuritis : an updated meta-analysis", Acta Neurol Scand, 146, pp.429~439 (2022)

관련 논문AI추천